Cytokines, such as interleukin (IL)-23, are key drivers of intestinal inflammation in patients with inflammatory bowel disease. While all IL-23–targeted agents neutralize IL-23, differences in antibody structure can improve the ability of these agents to capture this inflammatory cytokine from …
Cytokines, such as interleukin (IL)-23, are key drivers of intestinal inflammation in patients with inflammatory bowel disease. While all IL-23–targeted agents neutralize IL-23, differences in antibody structure can improve the ability of these agents to capture this inflammatory cytokine from …
Neuromyelitis optica spectrum disorder (NMOSD) is a relatively new term for a group of rare, demyelinating autoimmune diseases affecting the central nervous system (CNS), particularly the optic nerves and spinal cord. In the past, NMOSD was conflated with multiple sclerosis …
Neuromyelitis optica spectrum disorder (NMOSD) is a relatively new term for a group of rare, demyelinating autoimmune diseases affecting the central nervous system (CNS), particularly the optic nerves and spinal cord. In the past, NMOSD was conflated with multiple sclerosis …
Anemia occurs frequently in patients with inflammatory bowel disease (IBD) and is one of the most commonly seen extraintestinal manifestations of disease with iron deficiency (ID) as the most common cause. Practice guidelines recommend screening all patients with IBD regularly …
Interleukin (IL)-23 has been identified as a main driver of inflammation in inflammatory bowel disease (IBD) and has been identified as a target for highly effective advanced therapies. While all agents in the anti-IL-23 class of monoclonal antibodies (mABs) neutralize …
Patients with Crohn’s disease (CD) frequently experience bowel urgency, a symptom resulting in rushing to the bathroom and sometimes causing loss of bowel control. The symptom of bowel urgency dramatically impacts patient quality of life (QoL), and can lead to …
Anemia occurs frequently in patients with inflammatory bowel disease (IBD) and is one of the most commonly seen extraintestinal manifestations of disease with iron deficiency (ID) as the most common cause. Practice guidelines recommend screening all patients with IBD regularly …
Interleukin (IL)-23 has been identified as a main driver of inflammation in inflammatory bowel disease (IBD) and has been identified as a target for highly effective advanced therapies. While all agents in the anti-IL-23 class of monoclonal antibodies (mABs) neutralize …